November 28, 1989 |
Newport Pharmaceuticals announced Monday that it is resuming efforts to obtain approval for the sale of Isoprinosine to people infected with the AIDS virus, reversing a decision made a year ago to stop all research and testing on the drug.
June 20, 1990 |
Interest in an all but forgotten experimental AIDS drug, isoprinosine--manufacturered by Newport Pharmaceuticals International Inc. of Laguna Hills--has been renewed by the New England Journal of Medicine's decision to publish a favorable Scandinavian study of the medication. "Treatment with isoprinosine appears to delay progression to AIDS" in infected individuals, Dr.
October 2, 1990 |
Newport Pharmaceuticals and its liability insurer have tentatively agreed to pay about $5.7 million to settle two shareholders' lawsuits alleging that the company misled investors in promoting an anti-AIDS drug in 1985 and 1986, the company said Monday. The civil lawsuits, which make identical complaints, were filed separately in state and federal courts in September, 1986.
June 19, 1990 |
Newport Pharmaceuticals said Monday that a leading medical journal has agreed to publish a study of the company's drug, Isoprinosine, in the fight against HIV, the virus that causes AIDS. The Laguna Hills-based company said it would release further details Thursday at a press conference at the International AIDS Conference in San Francisco. Newport stock has shot up 66% since Thursday and closed Monday at $2.8125 in over-the-counter trading.
November 2, 1988 |
Newport Pharmaceuticals International Inc. reported Tuesday a $1.6-million loss for the third quarter. The company said the cost of clinical testing of isoprinosine, a drug believed to slow the advance of the AIDS virus, accounted for most of the loss. The company has said it will probably give up its 14-year battle to get Food and Drug Administration approval to sell the drug in the United States if the tests are disappointing.
September 25, 1988 |
Newport Pharmaceuticals International is yet another example of an Orange County company with a potentially hot product that has had trouble getting government approval. As a result, the company's stock price has undergone wild gyrations. A few analysts, however, are betting that a new, nearly completed study will provide enough ammunition to allow Newport Pharmaceuticals to submit its isoprinosine drug for Federal Drug Administration review as an AIDS treatment by the end of the year.